ESR1 and breast carcinoma: Given that dysregulation of ERα signaling is responsible for breast cancer progression and endocrine resistance, further investigation of new regulators of ERα signaling will facilitate the development of more effective therapeutic strategies to overcome endocrine resistance and inhibit tumor progression.